ATE403714T1 - Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen - Google Patents

Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen

Info

Publication number
ATE403714T1
ATE403714T1 AT97946457T AT97946457T ATE403714T1 AT E403714 T1 ATE403714 T1 AT E403714T1 AT 97946457 T AT97946457 T AT 97946457T AT 97946457 T AT97946457 T AT 97946457T AT E403714 T1 ATE403714 T1 AT E403714T1
Authority
AT
Austria
Prior art keywords
tnf
trre
preparations
necrosis factor
tumor necrosis
Prior art date
Application number
AT97946457T
Other languages
English (en)
Inventor
Gale Granger
Tetsuya Gatanaga
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE403714T1 publication Critical patent/ATE403714T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97946457T 1996-11-06 1997-11-05 Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen ATE403714T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3076196P 1996-11-06 1996-11-06

Publications (1)

Publication Number Publication Date
ATE403714T1 true ATE403714T1 (de) 2008-08-15

Family

ID=21855891

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97946457T ATE403714T1 (de) 1996-11-06 1997-11-05 Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen

Country Status (14)

Country Link
US (3) US6569664B1 (de)
EP (1) EP0938548B1 (de)
JP (1) JP2001508648A (de)
KR (1) KR100533531B1 (de)
AT (1) ATE403714T1 (de)
AU (1) AU744873B2 (de)
BR (1) BR9712900A (de)
CA (1) CA2270898A1 (de)
DE (1) DE69738887D1 (de)
ID (1) ID22049A (de)
IL (1) IL129787A0 (de)
NO (1) NO992187L (de)
NZ (1) NZ335864A (de)
WO (1) WO1998020140A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
CA2270898A1 (en) * 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
US6503511B1 (en) * 1998-04-07 2003-01-07 Medimmune, Inc. Derivatives of choline binding proteins for vaccines
US6911314B2 (en) 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
AU2001238076A1 (en) * 2000-02-11 2001-08-20 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
AU2001245371A1 (en) 2000-02-28 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
WO2004096207A1 (ja) * 2003-04-30 2004-11-11 Ajinomoto Co., Inc. 体温低下抑制剤
EP1699478A2 (de) * 2003-09-23 2006-09-13 Meyer Pharmaceuticals, LLC Behandlung von entzündung mit einem biologischen mittel, das zur freisetzung von zytokin-rezeptoren aus zellen führt
WO2005087947A2 (en) * 2004-03-09 2005-09-22 Meyer Pharmaceuticals Llc Bioengineered proteolytic enzymes with enhanced specificity for cytokine receptors
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
WO2007022474A2 (en) * 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
NZ572765A (en) 2006-06-30 2012-08-31 Abbott Biotech Ltd Automatic injection device with rod driving syringe longitudinally split with radially compressible pair of wings along its length
US9002096B2 (en) 2009-01-06 2015-04-07 Siemens Healthcare Diagnostics Inc. Method and apparatus for determining a liquid level in a container using imaging
PH12013501532A1 (en) 2011-01-24 2013-09-16 Abbvie Biotechnology Ltd Automatic injection devices having overmolded gripping surfaces

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4340586A (en) 1977-02-18 1982-07-20 Adam Bekierkunst Pharmaceutical preparation for treating disorders of the skin
US5192537A (en) 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5643740A (en) 1983-02-24 1997-07-01 Ronald J. Billing Monoclonal antibody specific for activated lymphocytes and monocytes
US5001061A (en) * 1983-06-22 1991-03-19 Lubrizol Genetics, Inc. nifD promoter of Bradyrhizobium
DE3343530A1 (de) 1983-12-01 1985-06-13 Max Planck Gesellschaft Arzneimittel mit verbesserter penetration der gewebsmembran
ATE73345T1 (de) 1984-10-19 1992-03-15 Chiron Corp Anregung zur heilung einer wunde mittels menschlichen hautwachstumsfaktors hergestellt durch rekombinant-dns.
JPH088870B2 (ja) 1985-02-05 1996-01-31 サイナ−ゲン バイオロジカルズ，インコ−ポレ−テツド メタロプロテイナ−ゼ阻害剤の配列をもつ組換ベクタ−系及びメタロプロテイナ−ゼ阻害剤製造のための組換ｄｎａ
US4695590A (en) 1986-05-05 1987-09-22 California Health Technologies Method for retarding aging
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US6869924B1 (en) 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
DE69033982T2 (de) 1989-03-21 2002-10-24 The United States Of America, Represented By The Secretary Matrizenmetalloproteinase-inhibitor-peptide
US5140043A (en) 1989-04-17 1992-08-18 Duke University Stable ascorbic acid compositions
US5130298A (en) 1989-05-16 1992-07-14 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
US6232446B1 (en) * 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
AU6501390A (en) 1989-09-21 1991-04-18 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5270326A (en) 1990-11-21 1993-12-14 University Of Florida Treatment for tissue ulceration
US5268384A (en) 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
JP3068879B2 (ja) 1991-03-09 2000-07-24 フマキラー株式会社 精製ダニアレルゲン
DE69226487T2 (de) 1991-09-26 1999-02-18 Nippon Zoki Pharmaceutical Co., Ltd., Osaka Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten
CA2120153C (en) 1991-09-30 2006-06-06 Ira Pastan Recombinant immunotoxins
EP0563485A1 (de) 1992-03-30 1993-10-06 Schering-Plough In-vitro-Erzeugung von menschlichen dendritischen Zellen
IL101769A (en) 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
AU6554294A (en) 1993-04-07 1994-10-24 Glycomed Incorporated Synthetic matrix metalloprotease inhibitors and uses thereof
WO1995009913A1 (en) 1993-10-07 1995-04-13 Incyte Pharmaceuticals, Inc. Human monocyte/macrophage derived metalloproteinase inhibitor
IL107268A0 (en) * 1993-10-12 1994-01-25 Yeda Res & Dev Molecules influencing the shedding of the tnf receptor, their preparation and their use
ES2216005T3 (es) 1993-11-09 2004-10-16 Targeted Genetics Corporation Produccion de titulos elevados de vectores de aav recombinantes.
DE69533606T2 (de) * 1994-01-28 2006-03-02 Ajinomoto Co., Inc. Transglutaminase aus japanischer auster
IL111125A0 (en) 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
IL114418A0 (en) 1994-07-07 1995-10-31 Res Dev Foundation Tumor necrosis factor receptor-II associated protein kinase and methods for its use
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6090605A (en) 1996-03-11 2000-07-18 The Board Of Trustees Of The University Of Arkansas Purified porcine kidney L-fucose kinase
US6068838A (en) 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
US5834236A (en) 1996-06-27 1998-11-10 The Salk Institute For Biological Studies AATT repeat transcription enhancer element
US5853977A (en) * 1996-07-12 1998-12-29 Schering Corporation Mammalian TNF-α convertases
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
CA2270898A1 (en) * 1996-11-06 1998-05-14 The Regents Of The University Of California Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
NZ337703A (en) 1997-03-05 2001-05-25 Univ Washington A screening method to identify agents that selectively inhibit Hepatitis C virus replication in viruses that contain an ISDR region
US6183997B1 (en) 1997-03-21 2001-02-06 Stratagene Polymerase enhancing factor (PEF) extracts PEF protein complexes isolated PEF proteins and methods for purifying and identifying same

Also Published As

Publication number Publication date
WO1998020140A1 (en) 1998-05-14
ID22049A (id) 1999-08-26
KR20000053073A (ko) 2000-08-25
AU5162198A (en) 1998-05-29
NO992187D0 (no) 1999-05-05
EP0938548A1 (de) 1999-09-01
US6858402B2 (en) 2005-02-22
AU744873B2 (en) 2002-03-07
KR100533531B1 (ko) 2005-12-06
BR9712900A (pt) 2000-11-28
US6573062B1 (en) 2003-06-03
NO992187L (no) 1999-07-01
JP2001508648A (ja) 2001-07-03
CA2270898A1 (en) 1998-05-14
US20030170776A1 (en) 2003-09-11
EP0938548B1 (de) 2008-08-06
NZ335864A (en) 2001-09-28
DE69738887D1 (de) 2008-09-18
US6569664B1 (en) 2003-05-27
IL129787A0 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
ATE403714T1 (de) Tumor necrosis factor rezeptor abspaltendes enzym,dessen zubereitungen und verwendungen
Sulli et al. Melatonin serum levels in rheumatoid arthritis
ATE281840T1 (de) Behandlung von diarrhoe
Majka et al. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization
EP0961833A4 (de) Hyaluronidase aus menschlichem plasma
ATE188969T1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
Cutolo et al. Circadian rhythms: glucocorticoids and arthritis
ATE347366T1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
Gallicchio et al. Modulation of murine pluripotential stem cell proliferation in vivo by lithium carbonate
WO2003025149A3 (en) Cell populations which co-express cd49c and cd90
WO1999038964A3 (en) Promoter regions of the mouse and human telomerase rna component genes
Houghtling et al. Acute effects of morphine on blood lymphocyte proliferation and plasma IL‐6 levels
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
Evans et al. Natural human IL-1β exhibits regulatory actions on human bone-derived cells invitro
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
Naveau et al. Interleukin-1 receptor antagonist plasma concentration is specifically increased by alpha-2A-interferon treatment
Ujioka et al. Analysis of the cytokine interaction among interleukin-1β, interleukin-8, and interleukin-1 receptor antagonist in the rabbit ovulatory process
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
Balakrishnan et al. Anticonvulsant activity of omeprazole in rats
Capelletto et al. Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
Elmazoglu et al. AB0107 S-ALLYL-L-CYSTEINE ATTENUATES INFLAMMATION RELATED OXIDATIVE STRESS PARAMETERS AND INCREASES ADHESION CAPACITY OF PRIMARY HUMAN OSTEOARTHRITIC ARTICULAR CHONDROCYTES
Corbacioglu et al. Incidence of Post-Hematopoietic Stem Cell Transplantation (HSCT) Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) without Hyperbilirubinemia at Diagnosis and Efficacy of Defibrotide in an Expanded-Access Program
Piantoni et al. A8. 25 The effect of abatacept therapy on granzyme B serum levels in patients with rheumatoid arthritis
Stauffer Isoforms and alternative splicing of the plasma membrane calcium ATPase

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties